Legislation considered under suspension of the Rules of the House of Representatives during the week of July 20, 2026

The Majority Leader of the House of Representatives announces bills that will be considered under suspension of the rules in that chamber. Under suspension, floor debate is limited, all floor amendments are prohibited, points of order against the bill are waived, and final passage requires a two-thirds majority vote.

At the request of the Majority Leader and the House Committee on the Budget, CBO estimates the effects of those bills on direct spending and revenues. CBO has limited time to review the legislation before consideration. Although it is possible in most cases to determine whether the legislation would affect direct spending or revenues, time may be insufficient to estimate the magnitude of those effects. If CBO has prepared estimates for similar or identical legislation, a more detailed assessment of budgetary effects, including effects on spending subject to appropriation, may be included.

CBO’s estimates of the bills that have been posted for possible consideration under suspension of the rules during the week of July 20, 2026, include: 

•  H.R. 1118, Value Over Cost Act of 2025, as amended
• H.R. 1493, To reauthorize and make improvements to Federal programs relating to the prevention, detection, and treatment of traumatic brain injuries, and for other purposes 
• H.R. 1703, Choices for Increased Mobility Act of 2025 
• H.R. 1722, Billion Dollar Boondoggle Act of 2025, as amended
• H.R. 2001, To amend the Public Health Service Act to reauthorize a grant program for addressing dental workforce needs, as amended 
• H.R. 2069, Stop Secret Spending Act of 2025, as amended 
• H.R. 2715, Destruction of Hazardous Imports Act, as amended 
• H.R. 2821, FDA Modernization Act 3.0 
• H.R. 2985, Modernizing Government Technology Reform Act, as amended 
• H.R. 3029, Nucleic Acid Standards for Biosecurity Act, as amended 
• H.R. 3491, DeOndra Dixon INCLUDE Project Act of 2025 
• H.R. 3747, Accelerating Access to Dementia and Alzheimer’s Provider Training (AADAPT) Act, as amended 
• H.R. 4123, FIT Procurement Act, as amended 
• H.R. 4348, To reauthorize the Kay Hagan Tick Act, and for other purposes 
• H.R. 4541, EARLY Act Reauthorization of 2025, as amended 
• H.R. 5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, as amended 
• H.R. 5578, Expanding Whistleblower Protections for Contractors Act of 2025, as amended
• H.R. 6238, NIH IMPROVE Act, as amended 
• H.R. 6330, Federal Relocation Payment Improvement Act, as amended 
• H.R. 7283, Ensuring Federal Purchasing Efficiency Act, as amended 
• H.R. 8205, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, as amended 
• H.R. 8209, School-Based Health Centers Reauthorization Act of 2026 
• H.R. 8720, Campaign Finance Transparency Act, as amended
• H.R. 8790, Next-Generation Geothermal Research and Development Act, as amended 
• H.R. 8823, Putting Patients First by Strengthening Provider Accountability in FECA Act, as amended